Liquidia Co. (NASDAQ:LQDA) CFO Michael Kaseta Sells 8,283 Shares

Liquidia Co. (NASDAQ:LQDA) CFO Michael Kaseta sold 8,283 shares of the business’s stock in a transaction on Monday, April 14th. The stock was sold at an average price of $13.57, for a total transaction of $112,400.31. Following the completion of the transaction, the chief financial officer now owns 396,315 shares in the company, valued at $5,377,994.55. This represents a 2.05 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Liquidia Price Performance

Liquidia stock opened at $13.72 on Friday. Liquidia Co. has a 12 month low of $8.26 and a 12 month high of $16.81. The company has a fifty day moving average price of $14.70 and a two-hundred day moving average price of $12.76. The company has a market cap of $1.17 billion, a PE ratio of -8.42 and a beta of 0.23.

Liquidia (NASDAQ:LQDA) last posted its quarterly earnings results on Wednesday, March 19th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.08). The business had revenue of $2.92 million during the quarter, compared to analyst estimates of $4.60 million. Liquidia had a negative net margin of 765.38% and a negative return on equity of 163.21%. Equities research analysts anticipate that Liquidia Co. will post -1.51 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. Wells Fargo & Company began coverage on Liquidia in a report on Friday, December 20th. They issued an “overweight” rating and a $20.00 price target for the company. Needham & Company LLC reiterated a “buy” rating and set a $25.00 target price on shares of Liquidia in a research note on Thursday, April 10th. Scotiabank restated an “outperform” rating on shares of Liquidia in a research note on Thursday, March 20th. Finally, HC Wainwright reiterated a “buy” rating and set a $29.00 price objective on shares of Liquidia in a research note on Thursday, March 20th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $26.63.

Hedge Funds Weigh In On Liquidia

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Corebridge Financial Inc. boosted its position in Liquidia by 2.3% during the 4th quarter. Corebridge Financial Inc. now owns 31,516 shares of the company’s stock valued at $371,000 after purchasing an additional 694 shares during the period. Catalina Capital Group LLC lifted its stake in Liquidia by 6.5% in the fourth quarter. Catalina Capital Group LLC now owns 18,307 shares of the company’s stock valued at $215,000 after buying an additional 1,125 shares during the last quarter. GAMMA Investing LLC boosted its holdings in shares of Liquidia by 65.6% during the first quarter. GAMMA Investing LLC now owns 2,961 shares of the company’s stock valued at $44,000 after acquiring an additional 1,173 shares during the period. Cetera Investment Advisers grew its position in shares of Liquidia by 4.3% during the fourth quarter. Cetera Investment Advisers now owns 31,243 shares of the company’s stock worth $367,000 after acquiring an additional 1,277 shares during the last quarter. Finally, Summit Investment Advisors Inc. increased its holdings in shares of Liquidia by 35.0% in the 4th quarter. Summit Investment Advisors Inc. now owns 6,632 shares of the company’s stock worth $78,000 after acquiring an additional 1,719 shares during the period. 64.54% of the stock is currently owned by institutional investors and hedge funds.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).